The 13.8-point gross margin range over five quarters points to a business largely exposed to input costs and realized pricing rather than structural cost advantage, so the 5.5% reading in 2026Q3 should not be annualized without evidence of sustained tissue and paperboard pricing. Operating margin of 0.6% on $384.9M of quarterly revenue implies overhead reductions, not revenue recovery, are doing the work, and net margin of -0.4% confirms that even the improved quarter did not translate into earnings. Investors should treat the reported net margin as depressed by non-recurring items given the swing to 9.9% in 2025Q4, which appears isolated rather than representative of underlying earning power.

ROIC remaining pinned near zero while asset turnover sits at just 0.23 versus Sylvamo's implied higher turnover suggests the problem is capacity utilization and margin, not balance sheet efficiency alone, and the 0.2% ROIC in 2026Q3 alongside -0.2% ROE signals equity holders are not being compensated. The 2024Q4 ROE of -14.2% and retained earnings erosion of roughly $54M through 2026Q3 imply capital has been destroyed rather than compounded over the period. A caveat: the PPE step-up to $2.4B and goodwill drop to $2.1M at 2025Q4 suggest reclassification, so the denominator of ROIC may have shifted and comparability across the ten quarters warrants further investigation.

Coverage of 0.52x in 2026Q3, following -2.51x and -4.16x in the two prior quarters, indicates interest is being met from cash balances or working capital releases rather than earnings, a pattern that appears increasingly uncomfortable if EBITDA remains near trough. The D/EBITDA reading of 260.24x in 2026Q3 versus 9.09x in 2025Q2 is arithmetically driven by collapsed trailing EBITDA rather than a proportional debt spike, so both metrics should be monitored together before concluding solvency is impaired. Compared with peers, SLVM carries a similar 0.88 D/E but with 7.8% ROE and positive coverage, implying CLW's leverage is structurally less serviceable at current operating performance.

With inventory at 65 days of cost of goods and DSO at 39 days, a quick ratio of 0.98 suggests the company leans materially on inventory realization to meet current liabilities, which is a weaker position in a downcycle where tissue and paperboard pricing is soft. The deterioration coincides with debt rising to $650.6M against $35.7M of cash, so the liquidity cushion appears to have been used rather than supplemented by the recent borrowing. Stress-tested against the 2026Q2 working capital source of $72.2M, which reversed to a $64.6M use in 2026Q3, the ratio path suggests volatility in the current position that investors should monitor quarter to quarter.

A 0.38x P/B sits well below SLVM's 1.38x and CASY's 6.64x, but with ROE at -0.2% and retained earnings eroding, the discount reflects genuinely subpar returns rather than simple mispricing, so book value support depends on the integrity of the $2.4B net PPE carrying value. The forward EV/EBITDA of 14.47x more than doubling the trailing 7.0x implies consensus expects EBITDA to fall further, which is directionally consistent with the negative trailing P/E of -16.71 and three consecutive quarters of revenue decline. Compared with SLVM at 4.71x EV/EBITDA, CLW's multiple premium despite weaker margins suggests either expected stabilization or leverage-inflated enterprise value, and the P/S of 0.20x offers limited comfort while gross margin volatility persists.